Haemonetics vs Penumbra
Haemonetics and Penumbra are similar in size: $1.33bn and $1.40bn of revenue in their latest fiscal years. Penumbra grew faster (17.5% against -2.0%). Penumbra kept more of each dollar of sales as profit: a net margin of 12.7% against 7.3%. Penumbra carries less debt relative to equity (0.0% against 155.7%).
| Latest fiscal year | HaemoneticsHAE, 2026 | PenumbraPEN, 2025 |
|---|---|---|
| Revenue | $1.33bn | $1.40bn |
| Revenue growth | -2.0% | 17.5% |
| Net income | $97.3m | $178m |
| Operating margin | 11.7% | 13.5% |
| Net margin | 7.3% | 12.7% |
| Return on equity | 12.0% | 13.8% |
| Free cash flow | $260m | $175m |
| Cash | $245m | $187m |
| Total debt | $1.24bn | $0 |
| Debt to equity | 155.7% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $175m | $0 |
| Employees | — | 4,700 |
| Market value | $5.49bn | $12.69bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 62 (Moderate) | 44 (Weak) |
| Insider trades, 12 months | 1 buys, 0 sales | 0 buys, 32 sales |